P

    Pasithea Therapeutics Corp (KTTA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.57
    +0.01 (+2.50%)

    Market Cap: $18.71M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    58%(7/12)
    Avg Surprise
    -235.35%
    Streak
    2 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.21
    Range$-0.21 - $-0.21
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.48-128.6%
    60d ago$-0.21+0.0%
    30d ago$-0.21+0.0%
    7d ago$-0.21+0.0%
    Current$-0.21
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Dec 31, 2026
    EPS Consensus$0.06
    Range$0.06 - $0.06
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.06---
    Sep 26EST
    		-$-0.21---
    Jun 26
    		$-0.16$-0.16+0.00%Beat+75.8%
    Mar 26
    		$-0.12N/A+73.33%Beat+92.5%
    Dec 25
    		$-0.89$-0.18-394.44%Miss+64.8%
    Sep 25
    		$-0.41N/AN/ABeat+85.7%
    Jun 25
    		$-0.66$0.00N/AMiss+82.2%
    Mar 25
    		$-1.61N/AN/ABeat+56.5%
    Dec 24
    		$-2.53N/AN/ABeat+47.8%
    Sep 24
    		$-2.87N/AN/ABeat-1900.7%
    Jun 24
    		$-3.71N/AN/ABeat-30.5%
    Mar 24
    		$-3.70N/AN/ABeat-49.9%
    Dec 23
    		$-4.85$-0.19-2450.84%Miss-2592.6%
    Sep 23
    		$-0.14$-0.18+20.22%Beat+95.5%
    Jun 23
    		$-2.84$-3.40+16.47%Beat-8.0%
    Mar 23
    		$-2.47$-3.40+27.35%Beat-18.2%
    Dec 22
    		$-0.18$-0.18+0.00%Beat-250.0%
    Sep 22
    		$-3.20$-2.80-14.29%Miss-2566.7%
    Jun 22
    		$-2.63$-2.20-19.55%Miss-5160.0%
    Mar 22
    		$-2.09$-0.40-422.50%Miss-2272.3%
    Dec 21
    		$0.12$-0.05+340.00%Beat+273.7%
    Sep 21
    		$-0.12N/AN/ABeat-6215.8%
    Jun 21
    		$-0.05$0.00N/AMiss-
    Mar 21
    		$-0.09$0.00N/AMiss-
    Dec 20
    		$-0.07$0.00N/AMiss-
    Jun 20
    		$-0.00$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.36EV/EBITDA2.90x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-65.50%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio26.25xQuick Ratio26.25x
    Trading Statistics
    Beta0.29Avg Volume211.61K
    52-Week High$2.0652-Week Low$0.28

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.53
    SMA 20$0.50
    SMA 50$0.50
    SMA 200$0.74
    EMA 10$0.54
    EMA 20$0.52
    EMA 50$0.53
    EMA 200$0.68

    MACD

    Line: 0.02Signal: 0.01Hist: 0.01

    ADX

    ADX: 23.1+DI: 21.5-DI: 9.7

    Aroon & PSAR

    Aroon Up96.0
    Aroon Down8.0
    PSAR$0.48

    Bollinger Bands

    Upper Band$0.59
    Lower Band$0.42
    %B Position3311%(Upper)
    Band Width0.93

    RSI (14-Day)

    Neutral
    62.5

    Momentum Oscillators

    Stoch %K78.8
    Stoch %D83.3
    Williams %R-18.5
    ROC (10d)20.1%
    Momentum0.10
    CCI (20d)136.5
    MFI (14d)82.8

    Volatility Measures

    ATR (14d)$0.05(7.9%)
    StdDev (20d)0.04
    Hist Vol93.9%(High)

    Volume Flow

    VWAP$0.57
    OBV699.6M
    AD Line-339.4M
    CMF (20d)-0.121

    Volume Metrics

    Avg Vol (20d)205.1K
    Vol Ratio2.2x(High)
    VWMA (20d)$0.51

    Pivot Points

    R3$0.67
    R2$0.64
    R1$0.60
    Pivot Point$0.57
    S1$0.53
    S2$0.50
    S3$0.46

    Advanced Oscillators

    TSI15.51
    Ultimate Osc54.5
    KST108.97

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$649,028$0$0$0$976,306$0
    Cost of Revenue$0$0$157,962$0$0$0$162,258$0$0$0$162,221$0
    Gross Profit$0$0$-157,962$0$0$0$-162,258$0$0$0$-162,221$0
    Operating Expenses$5.71M$4.88M$10.26M$3.11M$3.81M$3.68M$3.26M$3.00M$3.95M$4.04M$5.15M$3.79M
    R&D$3.69M$2.94M$2.74M$1.36M$2.15M$1.73M$1.51M$1.58M$2.36M$1.75M$3.35M$1.62M
    SG&A$2.03M$1.93M$7.51M$1.75M$1.66M$1.95M$1.75M$1.42M$1.59M$2.29M$1.80M$2.16M
    Operating Income$-5,713,282$-4,876,644$-10,256,162$-3,110,055$-3,810,899$-3,680,179$-3,259,550$-3,004,604$-3,945,034$-4,040,774$-5,148,782$-3,789,326
    Interest Income$410,416$450,338$182,128$43,396$54,424$47,245$80,483$75,076$114,407$153,218$0$131,740
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-5,273,852$-2,869,482$-10,110,868$-3,037,420$-3,716,157$-3,563,238$-3,177,661$-2,999,834$-3,866,249$-3,860,840$-5,031,264$-3,612,590
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-5,273,852$-2,869,482$-10,110,868$-3,037,420$-3,716,157$-3,563,238$-3,177,661$-2,999,834$-3,866,249$-3,860,840$-5,048,159$-3,612,590
    EBITDA$-5,526,727$-3,162,279$-10,128,284$-2,899,224$-3,609,491$-3,440,950$-3,100,656$-2,907,883$-3,818,400$-3,851,800$-5,152,671$-3,582,074
    EBIT$-5,684,268$-3,319,820$-10,285,825$-3,080,816$-3,770,581$-3,603,312$-3,262,914$-3,070,140$-3,980,656$-4,014,058$-5,314,892$-3,744,330
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about KTTA

    News

    Pasithea Therapeutics Received Notice of Noncompliance

    Pasithea Therapeutics (KTTA) received a notice of noncompliance from Nasdaq due to its stock price falling below the $1.00 minimum bid requirement. Nasdaq granted the company a 180-day extension until February 16, 2027, to regain compliance, with a reverse stock split being a potential action. Failure to comply could lead to delisting.

    TradingView•8/21/26•
    Bearish

    Pasithea (NASDAQ: KTTA) gets Nasdaq reprieve before possible delisting

    Pasithea Therapeutics Corp. (NASDAQ: KTTA) has received an additional 180-day extension from Nasdaq, pushing its compliance deadline to February 16, 2027, to meet the $1.00 minimum bid price requirement. The company was initially notified of non-compliance on February 20, 2026, and its initial grace period was set to expire on August 19, 2026. Pasithea may consider a reverse stock split to regain compliance, and failure to do so could lead to delisting proceedings.

    Stock Titan•8/21/26•
    Somewhat-Bearish

    Pasithea Therapeutics Corp. Q2 2026: Net loss $(5.27M), EPS $(0.16) — 10-Q Summary

    Pasithea Therapeutics Corp. reported a Q2 2026 net loss of $(5.27M) and diluted EPS of $(0.16), marking a wider loss compared to the previous year. The company is advancing its PAS-004 clinical development programs, with a significant increase in R&D expenses. Pasithea has refocused its pipeline on PAS-004 and discovery-stage PAS-001, discontinuing PAS-003.

    TradingView•8/15/26•
    Somewhat-Bearish

    Vivo Opportunity entities disclose 9.99% Pasithea Therapeutics (KTTA) holdings via warrants and stock

    Vivo Opportunity entities, including Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity Cayman Fund, L.P., have reported beneficial ownership of 9.99% of Pasithea Therapeutics (KTTA) common stock. These holdings comprise a mix of common shares and pre-funded warrants, which include provisions to prevent ownership exceeding 9.99%. The ownership percentages are based on 33,414,448 shares outstanding as of May 13, 2026.

    Stock Titan•8/14/26•
    Neutral

    Enterprise value to EBIT forward of Pasithea Therapeutics Corp. – NASDAQ:KTTAW

    This article provides financial information for Pasithea Therapeutics Corp. (NASDAQ: KTTAW), specifically focusing on its enterprise value to EBIT forward. It indicates that the company's financial data is provided by ICE Data Services and FactSet Research Systems Inc. The article is hosted on TradingView, a financial platform offering various market analysis tools.

    TradingView•8/11/26•
    Neutral

    Frequently Asked Questions About KTTA

    Does KTTA pay dividends?
    Pasithea Therapeutics Corp (KTTA) does not currently pay a regular dividend.
    What is KTTA's market cap?
    Pasithea Therapeutics Corp (KTTA) has a market capitalization of $18.71M with a current stock price of $0.57.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In